{"transactions":[{"id":2006712,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2023-02-17T23:09:58.000Z","date":"2023-02-15","kind":"exercise","acquired":false,"shares":7572,"price":25.8437,"value":195688.4964,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":7572},"source":{"system":"sec-edgar","filing":"0001562180-23-001533","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023001533/primarydocument.xml","form_type":"4"}},{"id":2006711,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2023-02-17T23:09:58.000Z","date":"2023-02-15","kind":"exercise","acquired":false,"shares":17428,"price":25.8437,"value":450404.0036,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":7.2,"expiration_date":"2025-06-01","underlying":"Common Stock","underlying_shares":17428},"source":{"system":"sec-edgar","filing":"0001562180-23-001533","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023001533/primarydocument.xml","form_type":"4"}},{"id":2006710,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-17T23:09:58.000Z","date":"2023-02-15","kind":"sale","acquired":false,"shares":17428,"price":25.8437,"value":450404.0036,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 443,841 options to purchase shares of common stock that are vested and immediately exercisable and a total of 202,500 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $25.53 to $26.10."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-23-001533","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023001533/primarydocument.xml","form_type":"4"}},{"id":2006709,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-17T23:09:58.000Z","date":"2023-02-15","kind":"exercise","acquired":true,"shares":17428,"price":7.2,"value":125481.6,"ownership":{"direct":true},"balance_after":17428,"source":{"system":"sec-edgar","filing":"0001562180-23-001533","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023001533/primarydocument.xml","form_type":"4"}},{"id":2006708,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-17T23:09:58.000Z","date":"2023-02-15","kind":"sale","acquired":false,"shares":7572,"price":25.8437,"value":195688.4964,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 443,841 options to purchase shares of common stock that are vested and immediately exercisable and a total of 202,500 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $25.53 to $26.10."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-23-001533","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023001533/primarydocument.xml","form_type":"4"}},{"id":2006707,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-17T23:09:58.000Z","date":"2023-02-15","kind":"exercise","acquired":true,"shares":7572,"price":6.38,"value":48309.36,"ownership":{"direct":true},"balance_after":7572,"source":{"system":"sec-edgar","filing":"0001562180-23-001533","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023001533/primarydocument.xml","form_type":"4"}},{"id":2032320,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2023-02-03T21:59:20.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":90000,"price":28.55,"value":2569500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":90000,"derivative":{"exercise_price":28.55,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001562180-23-000950","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023000950/primarydocument.xml","form_type":"4"}},{"id":2032319,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-03T21:59:20.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":69,"price":28.4281,"value":1961.5389,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-23-000950","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023000950/primarydocument.xml","form_type":"4"}},{"id":2032318,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-02-03T21:59:20.000Z","date":"2023-01-31","kind":"other","acquired":true,"shares":69,"price":17.32,"value":1195.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 69 shares by the Reporting Person on 01/31/2023 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":69,"source":{"system":"sec-edgar","filing":"0001562180-23-000950","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218023000950/primarydocument.xml","form_type":"4"}},{"id":2097878,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-12-02T22:01:51.000Z","date":"2022-12-02","kind":"exercise","acquired":false,"shares":17200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":17200},"source":{"system":"sec-edgar","filing":"0001562180-22-008017","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022008017/primarydocument.xml","form_type":"4"}},{"id":2097877,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-12-02T22:01:51.000Z","date":"2022-12-01","kind":"exercise","acquired":false,"shares":3772,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.35,"expiration_date":"2024-12-18","underlying":"Common Stock","underlying_shares":3772},"source":{"system":"sec-edgar","filing":"0001562180-22-008017","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022008017/primarydocument.xml","form_type":"4"}},{"id":2097876,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-12-02T22:01:51.000Z","date":"2022-12-01","kind":"exercise","acquired":false,"shares":4028,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":4028},"source":{"system":"sec-edgar","filing":"0001562180-22-008017","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022008017/primarydocument.xml","form_type":"4"}},{"id":2097875,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-02T22:01:51.000Z","date":"2022-12-02","kind":"sale","acquired":false,"shares":17200,"price":25.0544,"value":430935.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,925 options to purchase shares of common stock that are vested and immediately exercisable and a total of 122,916 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $25.00 to $25.19."}],"balance_after":265,"source":{"system":"sec-edgar","filing":"0001562180-22-008017","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022008017/primarydocument.xml","form_type":"4"}},{"id":2097874,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-02T22:01:51.000Z","date":"2022-12-02","kind":"exercise","acquired":true,"shares":17200,"price":6.38,"value":109736.0,"ownership":{"direct":true},"balance_after":17465,"source":{"system":"sec-edgar","filing":"0001562180-22-008017","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022008017/primarydocument.xml","form_type":"4"}},{"id":2097873,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-02T22:01:51.000Z","date":"2022-12-01","kind":"sale","acquired":false,"shares":4028,"price":25.0114,"value":100745.9192,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,925 options to purchase shares of common stock that are vested and immediately exercisable and a total of 122,916 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $25.00 to $25.03."}],"balance_after":265,"source":{"system":"sec-edgar","filing":"0001562180-22-008017","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022008017/primarydocument.xml","form_type":"4"}},{"id":2097872,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-02T22:01:51.000Z","date":"2022-12-01","kind":"exercise","acquired":true,"shares":4028,"price":6.38,"value":25698.64,"ownership":{"direct":true},"balance_after":4293,"source":{"system":"sec-edgar","filing":"0001562180-22-008017","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022008017/primarydocument.xml","form_type":"4"}},{"id":2097871,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-02T22:01:51.000Z","date":"2022-12-01","kind":"sale","acquired":false,"shares":3772,"price":25.0114,"value":94343.0008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,925 options to purchase shares of common stock that are vested and immediately exercisable and a total of 122,916 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale prices ranged from $25.00 to $25.03."}],"balance_after":265,"source":{"system":"sec-edgar","filing":"0001562180-22-008017","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022008017/primarydocument.xml","form_type":"4"}},{"id":2097870,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-12-02T22:01:51.000Z","date":"2022-12-01","kind":"exercise","acquired":true,"shares":3772,"price":6.35,"value":23952.2,"ownership":{"direct":true},"balance_after":4037,"source":{"system":"sec-edgar","filing":"0001562180-22-008017","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022008017/primarydocument.xml","form_type":"4"}},{"id":2172679,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-08-26T20:14:47.000Z","date":"2022-08-24","kind":"exercise","acquired":false,"shares":22846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.32,"expiration_date":"2024-09-15","underlying":"Common Stock","underlying_shares":22846},"source":{"system":"sec-edgar","filing":"0001562180-22-006334","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006334/primarydocument.xml","form_type":"4"}},{"id":2172678,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-08-26T20:14:47.000Z","date":"2022-08-24","kind":"exercise","acquired":false,"shares":2154,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":6.35,"expiration_date":"2024-12-18","underlying":"Common Stock","underlying_shares":2154},"source":{"system":"sec-edgar","filing":"0001562180-22-006334","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006334/primarydocument.xml","form_type":"4"}},{"id":2172677,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-08-26T20:14:47.000Z","date":"2022-08-24","kind":"sale","acquired":false,"shares":2154,"price":25.0357,"value":53926.8978,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,647 options to purchase shares of common stock that are vested and immediately exercisable and a total of 148,194 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $25.00 to $25.18."}],"balance_after":265,"source":{"system":"sec-edgar","filing":"0001562180-22-006334","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006334/primarydocument.xml","form_type":"4"}},{"id":2172676,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-08-26T20:14:47.000Z","date":"2022-08-24","kind":"exercise","acquired":true,"shares":2154,"price":6.35,"value":13677.9,"ownership":{"direct":true},"balance_after":2419,"source":{"system":"sec-edgar","filing":"0001562180-22-006334","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006334/primarydocument.xml","form_type":"4"}},{"id":2172675,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-08-26T20:14:47.000Z","date":"2022-08-24","kind":"sale","acquired":false,"shares":22846,"price":25.0357,"value":571965.6022,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,647 options to purchase shares of common stock that are vested and immediately exercisable and a total of 148,194 options to purchase shares of common stock that have not yet vested."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale prices ranged from $25.00 to $25.18."}],"balance_after":265,"source":{"system":"sec-edgar","filing":"0001562180-22-006334","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006334/primarydocument.xml","form_type":"4"}},{"id":2172674,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-08-26T20:14:47.000Z","date":"2022-08-24","kind":"exercise","acquired":true,"shares":22846,"price":6.32,"value":144386.72,"ownership":{"direct":true},"balance_after":23111,"source":{"system":"sec-edgar","filing":"0001562180-22-006334","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006334/primarydocument.xml","form_type":"4"}},{"id":2172673,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-08-26T20:14:47.000Z","date":"2022-07-29","kind":"other","acquired":true,"shares":265,"price":14.12,"value":3741.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 265 shares by the Reporting Person on 07/29/2022 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":265,"source":{"system":"sec-edgar","filing":"0001562180-22-006334","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022006334/primarydocument.xml","form_type":"4"}},{"id":2413098,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-02-03T22:32:14.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":80000,"price":15.79,"value":1263200.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":80000,"derivative":{"exercise_price":15.79,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001562180-22-001079","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022001079/primarydocument.xml","form_type":"4"}},{"id":2413097,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-02-03T22:32:14.000Z","date":"2022-02-01","kind":"sale","acquired":false,"shares":1412,"price":16.65,"value":23509.8,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-22-001079","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022001079/primarydocument.xml","form_type":"4"}},{"id":2413096,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-02-03T22:32:14.000Z","date":"2022-01-31","kind":"other","acquired":true,"shares":1412,"price":12.39,"value":17494.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,412 shares by the Reporting Person on 01/31/2022 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":1412,"source":{"system":"sec-edgar","filing":"0001562180-22-001079","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022001079/primarydocument.xml","form_type":"4"}},{"id":2876354,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-05T21:22:26.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":80000,"derivative":{"exercise_price":21.36,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001562180-21-000934","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021000934/primarydocument.xml","form_type":"4"}},{"id":2965846,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-25T21:38:59.000Z","date":"2020-11-23","kind":"exercise","acquired":false,"shares":5684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.08,"expiration_date":"2023-05-09","underlying":"Common Stock","underlying_shares":5684},"source":{"system":"sec-edgar","filing":"0001562180-20-006920","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218020006920/primarydocument.xml","form_type":"4"}},{"id":2965845,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-25T21:38:59.000Z","date":"2020-11-23","kind":"exercise","acquired":false,"shares":24288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.08,"expiration_date":"2023-05-09","underlying":"Common Stock","underlying_shares":24288},"source":{"system":"sec-edgar","filing":"0001562180-20-006920","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218020006920/primarydocument.xml","form_type":"4"}},{"id":2965844,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-11-25T21:38:59.000Z","date":"2020-11-23","kind":"sale","acquired":false,"shares":16334,"price":22.8924,"value":373924.4616,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sales prices ranged from $22.34 to $23.32."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-20-006920","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218020006920/primarydocument.xml","form_type":"4"}},{"id":2965843,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-11-25T21:38:59.000Z","date":"2020-11-23","kind":"sale","acquired":false,"shares":7954,"price":23.5849,"value":187594.2946,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales prices ranged from $23.35 to $23.94."}],"balance_after":16334,"source":{"system":"sec-edgar","filing":"0001562180-20-006920","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218020006920/primarydocument.xml","form_type":"4"}},{"id":2965842,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-11-25T21:38:59.000Z","date":"2020-11-23","kind":"sale","acquired":false,"shares":5684,"price":23.3291,"value":132602.6044,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The sales prices ranged from $22.94 to $23.73."}],"balance_after":24288,"source":{"system":"sec-edgar","filing":"0001562180-20-006920","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218020006920/primarydocument.xml","form_type":"4"}},{"id":2965841,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-11-25T21:38:59.000Z","date":"2020-11-23","kind":"exercise","acquired":true,"shares":5684,"price":3.08,"value":17506.72,"ownership":{"direct":true},"balance_after":29972,"source":{"system":"sec-edgar","filing":"0001562180-20-006920","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218020006920/primarydocument.xml","form_type":"4"}},{"id":2965840,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-11-25T21:38:59.000Z","date":"2020-11-23","kind":"exercise","acquired":true,"shares":24288,"price":3.08,"value":74807.04,"ownership":{"direct":true},"balance_after":24288,"source":{"system":"sec-edgar","filing":"0001562180-20-006920","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218020006920/primarydocument.xml","form_type":"4"}},{"id":3270002,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-14T21:36:14.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":50000,"derivative":{"exercise_price":9.47,"expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001562180-20-001234","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218020001234/primarydocument.xml","form_type":"4"}},{"id":3667734,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-08T21:28:11.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The securities awarded on 02/06/2019 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 40,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/06/2019. Options to purchase 40,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones."}],"balance_after":80000,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001562180-19-000856","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218019000856/primarydocument.xml","form_type":"4"}},{"id":3971953,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-04-03T20:42:43.000Z","date":"2018-04-03","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.08,"expiration_date":"2023-05-09","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001562180-18-001800","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/primarydocument.xml","form_type":"4"}},{"id":3971952,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-04-03T20:42:43.000Z","date":"2018-04-03","kind":"sale","acquired":false,"shares":7500,"price":15,"value":112500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-18-001800","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/primarydocument.xml","form_type":"4"}},{"id":3971951,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-04-03T20:42:43.000Z","date":"2018-04-03","kind":"exercise","acquired":true,"shares":7500,"price":3.08,"value":23100.0,"ownership":{"direct":true},"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001562180-18-001800","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/primarydocument.xml","form_type":"4"}},{"id":4013986,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-05T21:04:29.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 48 successive equal monthly installments measured from February 8, 2018."}],"balance_after":40000,"derivative":{"exercise_price":9.4,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001562180-18-001428","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218018001428/primarydocument.xml","form_type":"4"}},{"id":4311407,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-05-19T15:27:06.000Z","date":"2017-05-17","kind":"exercise","acquired":false,"shares":732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.08,"expiration_date":"2023-05-09","underlying":"Common Stock","underlying_shares":732},"source":{"system":"sec-edgar","filing":"0001562180-17-002011","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218017002011/primarydocument.xml","form_type":"4"}},{"id":4311406,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-05-19T15:27:06.000Z","date":"2017-05-17","kind":"sale","acquired":false,"shares":5000,"price":15,"value":75000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-17-002011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218017002011/primarydocument.xml","form_type":"4"}},{"id":4311405,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2017-05-19T15:27:06.000Z","date":"2017-05-17","kind":"exercise","acquired":true,"shares":732,"price":3.08,"value":2254.56,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001562180-17-002011","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218017002011/primarydocument.xml","form_type":"4"}},{"id":4461205,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":116727,"kind":"person","name":"Ordentlich Peter","position":1,"cik":"0001594274","reported_name":"Ordentlich Peter","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-08T19:13:14.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 48 successive equal monthly installments measured from February 6, 2017."}],"balance_after":20000,"derivative":{"exercise_price":8.77,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-17-000570","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218017000570/primarydocument.xml","form_type":"4"}}]}